Company profile
Inhibikase Therapeutics, Inc. Insider Trading
IKTEvery SEC Form 4 insider trading filing for Inhibikase Therapeutics, Inc. (IKT) since April 2023 — open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC. Why 2023?
- Exchange
- Nasdaq
- Sector
- Biological Products, (No Diagnostic Substances)
- CIK
- 0001750149
- Filings
- 59
- Insiders
- 21
- Last filing
- 2026-07-30
Activity summary
Recent insider activity is bullish. Over the last 30 days, 2 insiders purchased shares (net $28K). Buying was led by Berman Dennis N.
Three year balance
Buy and sell value by quarter, Q2 23 to Q3 26. Inhibikase Therapeutics, Inc. insiders are net buyers across the period shown.
Bars below the rule are sales, above are purchases. Largest quarter on the chart is $3.0M.
90 day insight
Over the last 90 days, Inhibikase Therapeutics, Inc. insiders bought $28K across 8 transactions with no open-market sales.
- Most active insider: Berman Dennis N with 3 transactions totaling $28K.
- Largest single purchase: $28K by Berman Dennis N on Jul 30, 2026.
Activity skews bullish — buys outpace sales.
Insider Transactions
Sourced from SEC EDGAR Form 4 filings. Updated hourly.
| Date | Insider | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Berman Dennis N | IKT | Option Exercise | 21,854 | $1.26 | $28K |
| Jul 30, 2026 | Berman Dennis N | IKT | Option Exercise | 21,854 | — | — |
| Jul 29, 2026 | Ra Capital Management, L.p. | IKT | J | 18,030,000 | — | — |
| Jul 29, 2026 | Ra Capital Management, L.p. | IKT | J | 18,030,000 | — | — |
| Jun 26, 2026 | Aurentz Vincent | IKT | Award | 155,000 | — | — |
45 more transactions hidden
Free account · No credit card required
Building something? Get API access →
Query this yourself
The same rows, over the API.
curl "https://api.form4api.com/v1/transactions?ticker=IKT" \
-H "X-Api-Key: $KEY"Top insiders
By total value filed.
Institutional Ownership
Top 13F-HR holders of Inhibikase Therapeutics, Inc. as of 2026-06-30
Data source: quarterly 13F-HR filings — institutional holders report positions within 45 days of quarter end. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →